Krystal Biotech, Inc. (NASDAQ: KRYS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 39.47 | EPS (ttm) | 8.27 | Insider Own | 12.21% | Shs Outstand | 29.48M | Perf Week | -4.30% |
| Market Cap | 9.62B | Forward P/E | 36.07 | EPS next Y | 9.05 | Insider Trans | -5.72% | Shs Float | 23.51M | Perf Month | -12.06% |
| Enterprise Value | 9.20B | PEG | 0.64 | EPS next Q | - | Inst Own | - | Short Float | 14.87% | Perf Quarter | 10.03% |
| Income | 240.59M | P/S | 21.85 | EPS this Y | -0.33% | Inst Trans | - | Short Ratio | 10.91 | Perf Half Y | 21.97% |
| Sales | 440.48M | P/B | 7.09 | EPS next Y | 21.40% | ROA | 16.09% | Short Interest | 3.50M | Perf YTD | 32.41% |
| Book/sh | - | P/C | 35.40 | EPS next 5Y | 45.73% | ROE | 19.34% | 52W High | 381.58 -14.66% | Perf Year | 140.04% |
| Cash/sh | - | P/FCF | 37.33 | EPS past 3/5Y | - | ROIC | 14.39% | 52W Low | 131.98 146.73% | Perf 3Y | 158.51% |
| Dividend Est. | - | EV/EBITDA | 42.14 | Sales past 3/5Y | - | Gross Margin | 93.34% | Volatility | 5.02% 5.05% | Perf 5Y | 458.61% |
| Dividend TTM | - | EV/Sales | 20.90 | EPS Y/Y TTM | 149.33% | Oper. Margin | 44.93% | ATR (14) | 16.30 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.96 | Sales Y/Y TTM | 43.30% | Profit Margin | 54.82% | RSI (14) | 43.98 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.32 | EPS Q/Q | 52.50% | SMA20 | -4.37% | Beta | 0.51 | Target Price | 364.50 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | 31.82% | SMA50 | -3.79% | Rel Volume | 0.37 | Prev Close | 326.45 |
| Employees | 295 | LT Debt/Eq | 0.01 | Earnings | Nov 02 | SMA200 | 18.60% | Avg Volume | 427.83K | Price | 325.64 |
| IPO Date | Sep 20, 2017 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 22.80% 3.79% | Net Debt/EBITDA | -1.92 | Volume | 160,024 | Change | -0.25% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-13-26 | Reiterated | Jefferies | Buy | $399 → $474 |
| Jun-16-26 | Reiterated | HC Wainwright & Co. | Buy | $310 → $361 |
| May-05-26 | Reiterated | Evercore ISI Group | Outperform | $206 → $300 |
| Feb-18-26 | Reiterated | Chardan Capital | Buy | $216 → $323 |
| Feb-17-26 | Reiterated | Jefferies | Buy | $371 |
| Jan-09-26 | Reiterated | HC Wainwright & Co. | Buy | $310 |
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy | |
| Oct-17-25 | Reiterated | Guggenheim | Buy | $189 → $224 |
| Aug-22-25 | Reiterated | Chardan Capital | Buy | $133 → $216 |
| Sep-11-24 | Reiterated | Stifel Nicolaus | $204 → $220 |
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 440 | 389 | 291 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 29 | 29 | 20 | — | — | — | — | — | — | |
| Gross Profit | 411 | 360 | 270 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 160 | 147 | 114 | — | — | — | — | — | — | |
| Research and Development | 59 | 58 | 54 | — | — | — | — | — | — | |
| Other Operating Expense | -6 | -6 | 37 | — | — | — | — | — | — | |
| Operating Income | 197 | 161 | 66 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 30 | 28 | 30 | — | — | — | — | — | — | |
| Net Income Before Taxes | 226 | 189 | 95 | — | — | — | — | — | — | |
| Income Taxes | -14 | -15 | 6 | — | — | — | — | — | — | |
| Consolidated Net Income | 241 | 205 | 89 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 241 | 205 | 89 | — | — | — | — | — | — | |
| Net Income | 241 | 205 | 89 | — | — | — | — | — | — | |
| EPS (Recurring) | 8.27 | 7.08 | 3.12 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 8.27 | 7.08 | 3.12 | — | — | — | — | — | — | |
| EPS (Diluted) | 7.98 | 6.84 | 3.00 | — | — | — | — | — | — | |
| EBITDA | 219 | 196 | 110 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 40.81 | 36.04 | 52.22 | — | — | — | — | — | — | |
| Price To Sales Ratio | 22.20 | 18.38 | 15.61 | — | — | — | — | — | — | |
| Gross Margin | 93.41 | 92.54 | 92.78 | — | — | — | — | — | — | |
| Operating Margin | 44.77 | 41.39 | 22.68 | — | — | — | — | — | — | |
| Net Margin | 54.77 | 52.70 | 30.58 | — | — | — | — | — | — | |
| Shares Outstanding | 30 | 29 | 29 | — | — | — | — | — | — | |
| Market Capitalization | 9,769 | 7,150 | 4,543 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Thomas John Charles | EVP, General Counsel | Jun 25 '26 | Option Exercise | 179.25 | 1,000 | 179,250 | 1,000 | Jun 26 |
| Thomas John Charles | EVP, General Counsel | Jun 25 '26 | Sale | 347.27 | 1,000 | 347,270 | 0 | Jun 26 |
| Krishnan Suma | President, R&D | Jun 04 '26 | Sale | 308.11 | 25,000 | 7,702,826 | 1,378,155 | Jun 05 |
| Krishnan Krish S | President and CEO | Jun 04 '26 | Sale | 308.12 | 25,000 | 7,702,983 | 1,450,253 | Jun 05 |
| Thomas John Charles | EVP, General Counsel | May 26 '26 | Sale | 302.03 | 642 | 193,903 | 0 | May 27 |
| Krishnan Suma | President, R&D | Mar 04 '26 | Sale | 263.21 | 25,000 | 6,580,269 | 1,403,155 | Mar 06 |
| Krishnan Krish S | President and CEO | Mar 04 '26 | Sale | 263.17 | 25,000 | 6,579,164 | 1,475,253 | Mar 06 |
| ROMANO KATHRYN | Chief Accounting Officer | Mar 02 '26 | Sale | 267.60 | 750 | 200,700 | 22,366 | Mar 03 |
| ROMANO KATHRYN | Chief Accounting Officer | Feb 27 '26 | Option Exercise | 0.00 | 8,050 | 0 | 26,068 | Mar 03 |
| Krishnan Suma | President, R&D | Feb 27 '26 | Option Exercise | 0.00 | 67,225 | 0 | 1,509,075 | Mar 03 |
| Krishnan Krish S | President and CEO | Feb 27 '26 | Option Exercise | 0.00 | 67,225 | 0 | 1,509,075 | Mar 03 |
| JANNEY DANIEL | Director | Feb 27 '26 | Sale | 275.59 | 11,803 | 3,252,824 | 73,293 | Mar 03 |
| JANNEY DANIEL | Director | Feb 26 '26 | Sale | 275.63 | 7,741 | 2,133,679 | 85,096 | Feb 26 |
| JANNEY DANIEL | Director | Feb 25 '26 | Sale | 275.00 | 700 | 192,500 | 92,837 | Feb 26 |
| JANNEY DANIEL | Director | Feb 24 '26 | Sale | 267.27 | 51,720 | 13,823,202 | 0 | Feb 26 |